S. , Y. M. Munoz, A. Greenblatt, and R. , La cristallurie médicamenteuse Femmes et Observance dans le VIHDossier SIDALe rapport Delfraissy, la cuvée http://www.revihop06.org/articles/delfraissy2004.php 6HIV medicineGuidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescentsGuidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and AdolescentsPrise en charge thérapeutique des personnes infectées par le VIH-Rapport 2004-Recommandations du groupe d'expertsDosage des antirétroviraux chez les patients VIH+ Recommandations du groupe d'expertsAssociation of race and gender with HIV-1 RNA levels and immunologic progression, Utilisation médicale et interprétation des résultats des tests de résistance du VIH aux antirétrovirauxPrise en charge des personnes infectées par le VIH (Recommandations du groupe d'experts). Sous la direction du Professeur Jean-François Delfraissy. RapportPrise en charge médicale des personnes infectées par le VIH. Rapport, pp.218-244, 2000.

A. Antinori, F. Baldini, E. Girardi, A. Cingolani, M. Zaccarelli et al., Female sex and the use of anti-allergic agents increase the risk of developing cutaneous rash associated with nevirapine therapy, AIDS, vol.15, issue.12, pp.1579-81, 2001.
DOI : 10.1097/00002030-200108170-00018

M. Baylor, J. , and R. , Hepatotoxicity Associated With Nevirapine Use, JAIDS Journal of Acquired Immune Deficiency Syndromes, vol.35, issue.5, pp.538-547, 2004.
DOI : 10.1097/00126334-200404150-00014

S. Bersoff-matcha, W. Miller, J. Aberg, C. Van-der-horst, H. Jr et al., Sex Differences in Nevirapine Rash, Clinical Infectious Diseases, vol.32, issue.1, pp.124-133, 2001.
DOI : 10.1086/317536

P. Bonfanti, L. Valsecchi, F. Parazzini, S. Carradori, L. Pusterla et al., Incidence of Adverse Reactions in HIV Patients Treated With Protease Inhibitors: A Cohort Study, Coordinamento Italiano Studio Allergia e Infezione da HIV (CISAI) Group, pp.236-281, 2000.
DOI : 10.1097/00126334-200003010-00004

F. Bonnet, M. Bonarek, P. Morlat, P. Mercie, M. Dupon et al., Risk Factors for Lactic Acidosis in HIV???Infected Patients Treated with Nucleoside Reverse???Transcriptase Inhibitors: A Case???Control Study, Clinical Infectious Diseases, vol.36, issue.10, pp.1324-1332, 2003.
DOI : 10.1086/374601

T. Brown, M. Ruppe, R. Kassner, P. Kumar, T. Kehoe et al., Reduced Bone Mineral Density in Human Immunodeficiency Virus-Infected Patients and Its Association with Increased Central Adiposity and Postload Hyperglycemia, The Journal of Clinical Endocrinology & Metabolism, vol.89, issue.3, pp.1200-1206, 2004.
DOI : 10.1210/jc.2003-031506

E. Buira, J. Gatell, J. Miro, J. Batalla, L. Zamora et al., Influence of treatment with zidovudine (ZDV) on the long-term survival of AIDS patients, J Acquir Immune Defic Syndr, vol.5, issue.7, pp.737-779, 1992.

A. Butt, Fatal lactic acidosis and pancreatitis associated with ribavirin and didanosine therapy, AIDS Read, vol.13, issue.7, pp.344-352, 2003.

A. Carr, Lactic Acidemia in Infection with Human Immunodeficiency Virus, Clinical Infectious Diseases, vol.36, issue.s2, pp.96-100, 2003.
DOI : 10.1086/367565

R. Chaisson, J. Keruly, and R. Moore, Race, Sex, Drug Use, and Progression of Human Immunodeficiency Virus Disease, New England Journal of Medicine, vol.333, issue.12, pp.751-757, 1995.
DOI : 10.1056/NEJM199509213331202

D. Chan, S. Cheung, A. Gray, A. Ip, and B. Lee, Identifying the psychosocial correlates of condom use by female sex workers in Hong Kong, AIDS Care, vol.5, issue.4, pp.530-539, 2004.
DOI : 10.1080/08870440108405516

C. Chirouze and B. Hoen, Infection par le VIH, La revue du Praticien, vol.56, issue.9, pp.941-1012, 2006.

C. Chirouze, L. Hustache-mathieu, C. Rougeot, C. Drobacheff, H. Gil et al., Facteurs de risque de syndrome d'hypersensibilit?? ?? l'Abacavir en pratique clinique de routine, Pathologie Biologie, vol.52, issue.9, pp.529-562, 2004.
DOI : 10.1016/j.patbio.2004.07.012

R. Clark, Sex Differences in Antiretroviral Therapy-Associated Intolerance and Adverse Events, Drug Safety, vol.36, issue.3, pp.1075-83, 2005.
DOI : 10.2165/00002018-200528120-00003

R. Clark and K. Squires, Gender-specific considerations in the antiretroviral management of HIV-infected women, Expert Review of Anti-infective Therapy, vol.3, issue.2, pp.213-240, 2005.
DOI : 10.1586/14787210.3.2.213

S. Cohn, Women with HIV/AIDS: treating the fastest-growing populationHIV in Women: An Update, AIDS Read AIDS clinical Care, vol.13, issue.5, pp.241-243, 2002.

J. Currier and D. Havlir, Complications of HIV disease and antiretroviral therapy, Top HIV Med, vol.13, issue.1, pp.16-23, 2005.

J. Currier, C. Spino, J. Grimes, C. Wofsy, D. Katzenstein et al., Differences Between Women and Men in Adverse Events and CD4+ Responses to Nucleoside Analogue Therapy for HIV Infection, JAIDS Journal of Acquired Immune Deficiency Syndromes, vol.24, issue.4, pp.316-340, 2000.
DOI : 10.1097/00126334-200008010-00003

C. Danel, R. Moh, A. Minga, A. Anzian, O. Ba-gomis et al., CD4-guided structured antiretroviral treatment interruption strategy in HIV-infected adults in west Africa (Trivacan ANRS 1269 trial): a randomised trial, The Lancet, vol.367, issue.9527, pp.1981-1990, 2006.
DOI : 10.1016/S0140-6736(06)68887-9

P. Easterbrook, A. Waters, S. Murad, N. Ives, C. Taylor et al., Epidemiological risk factors for hypersensitivity reactions to abacavir*, HIV Medicine, vol.4, issue.4, pp.321-325, 2003.
DOI : 10.1086/317536

URL : http://www.scopus.com/inward/record.url?scp=0142155195&partnerID=8YFLogxK

W. El-sadr, J. Lundgren, J. Neaton, F. Gordin, D. Abrams et al., CD4+ countguided interruption of antiretroviral treatment, N Engl J Med, vol.355, issue.22, pp.2283-96, 2006.

J. Evans, T. Nims, J. Cooley, W. Bradley, L. Jagodzinski et al., Serum Levels of Virus Burden in Early???Stage Human Immunodeficiency Virus Type 1 Disease in Women, The Journal of Infectious Diseases, vol.175, issue.4, pp.795-800, 1997.
DOI : 10.1086/513973

J. Fagot, M. Mockenhaupt, J. Bouwes-bavinck, L. Naldi, C. Viboud et al., Nevirapine and the risk of Stevens???Johnson syndrome or toxic epidermal necrolysis, AIDS, vol.15, issue.14, pp.1843-1851, 2001.
DOI : 10.1097/00002030-200109280-00014

H. Farzadegan, D. Hoover, J. Astemborski, C. Lyles, J. Margolick et al., Sex differences in HIV-1 viral load and progression to AIDS, The Lancet, vol.352, issue.9139, pp.1510-1514, 1998.
DOI : 10.1016/S0140-6736(98)02372-1

A. Fausto, M. Bongiovanni, P. Cicconi, L. Menicagli, E. Ligabo et al., Potential predictive factors of osteoporosis in HIV-positive subjects, Bone, vol.38, issue.6, pp.893-900, 2006.
DOI : 10.1016/j.bone.2005.11.001

M. Floridia, R. Bucciardini, V. Fragola, C. Galluzzo, G. Giannini et al., Risk factors and occurrence of rash in HIV-positive patients not receiving nonnucleoside reverse transcriptase inhibitor: data from a randomized study evaluating use of protease inhibitors in nucleoside-experienced patients with very low CD4 levels (<50 cells/mmuL), HIV Medicine, vol.29, issue.1, pp.1-10, 2004.
DOI : 10.1097/00002030-200007280-00032

M. Galli, A. Cozzi-lepri, A. Ridolfo, C. Gervasoni, L. Ravasio et al., Incidence of Adipose Tissue Alterations in First-Line Antiretroviral Therapy, Archives of Internal Medicine, vol.162, issue.22, pp.2621-2629, 2002.
DOI : 10.1001/archinte.162.22.2621

M. Galli, A. Ridolfo, F. Adorni, A. Cappelletti, P. Morelli et al., Correlates of risk of adipose tissue alterations and their modifications over time in HIV-1-infected women treated with antiretroviral therapy, Antivir Ther, vol.8, issue.4, pp.347-54, 2003.

M. Galli, F. Veglia, G. Angarano, S. Santambrogio, E. Meneghini et al., Gender Differences in Antiretroviral Drug???Related Adipose Tissue Alterations, JAIDS Journal of Acquired Immune Deficiency Syndromes, vol.34, issue.1, pp.58-61, 2003.
DOI : 10.1097/00126334-200309010-00008

G. Gatti, D. Biagio, A. Casazza, R. , D. Pascalis et al., The relationship between ritonavir plasma levels and side-effects: implications for therapeutic drug monitoring, AIDS, vol.13, issue.15, pp.2083-2092, 1999.
DOI : 10.1097/00002030-199910220-00011

S. Grover, L. Coupal, N. Gilmore, and J. Mukherjee, Impact of dyslipidemia associated with Highly Active Antiretroviral Therapy (HAART) on cardiovascular risk and life expectancy**The sponsor provided the principal investigator with the results of study AI 424-008 before the study's subsequent publication but did not participate in the data analysis presented in this report. A draft of the manuscript was submitted to the sponsor before submission with the understanding that the final manuscript remained under the complete control of the principal investigator., The American Journal of Cardiology, vol.95, issue.5, pp.586-91, 2005.
DOI : 10.1016/j.amjcard.2004.11.004

H. Izzedine, V. Launay-vacher, and G. Deray, Antiviral Drug-Induced Nephrotoxicity, American Journal of Kidney Diseases, vol.45, issue.5, pp.804-821, 2005.
DOI : 10.1053/j.ajkd.2005.02.010

C. Junghans, B. Ledergerber, P. Chan, R. Weber, and M. Egger, Sex differences in HIV-1 viral load and progression to AIDS, The Lancet, vol.353, issue.9152, pp.589-590, 1999.
DOI : 10.1016/S0140-6736(05)75645-2

N. Kontorinis and D. Dieterich, Hepatotoxicity of antiretroviral therapy, AIDS Rev, vol.5, issue.1, pp.36-43, 2003.

H. Kremer and U. Sonnenberg-schwan, Women Living with HIV Does Sex and Gender Matter? A Current Literature Review, Eur J Med Res, vol.8, issue.1, pp.8-16, 2003.

K. Kress, Antiretroviral-associated hepatotoxicity, Current Infectious Disease Reports, vol.38, issue.Suppl 2, pp.103-107, 2005.
DOI : 10.1007/s11908-005-0068-z

L. Kuyper, E. Wood, J. Montaner, B. Yip, O. Connell et al., Gender Differences in HIV-1 RNA Rebound Attributed to Incomplete Antiretroviral Adherence Among HIV-Infected Patients in a Population-Based Cohort, JAIDS Journal of Acquired Immune Deficiency Syndromes, vol.37, issue.4, pp.1470-1476, 2004.
DOI : 10.1097/01.qai.0000138379.39317.62

M. Lagrange-xelot and J. Molina, Effets ind??sirables induits par les traitements antir??troviraux, La Presse M??dicale, vol.34, issue.20, pp.1571-1578, 2005.
DOI : 10.1016/S0755-4982(05)84227-7

J. Leitner, H. Pernerstorfer-schoen, A. Weiss, K. Schindler, A. Rieger et al., Age and sex modulate metabolic and cardiovascular risk markers of patients after 1 year of highly active antiretroviral therapy (HAART)Sustained control of viremia following therapeutic immunization in chronically HIV-1-infected individuals, Atherosclerosis. Aids, vol.56, issue.203, pp.405-418, 2005.

G. Lucas, R. Chaisson, and R. Moore, Highly Active Antiretroviral Therapy in a Large Urban Clinic: Risk Factors for Virologic Failure and Adverse Drug Reactions, Annals of Internal Medicine, vol.131, issue.2, pp.81-88, 1999.
DOI : 10.7326/0003-4819-131-2-199907200-00002

J. Lundgren, C. Pedersen, N. Clumeck, J. Gatell, A. Johnson et al., Survival differences in European patients with AIDS, 1979-89, BMJ, vol.308, issue.6936, pp.1068-73, 1994.
DOI : 10.1136/bmj.308.6936.1068

URL : http://www.bmj.com/cgi/content/short/308/6936/1068

A. Moore, A. Mocroft, S. Madge, H. Devereux, D. Wilson et al., Gender Differences in Virologic Response to Treatment in an HIV-Positive Population: A Cohort Study, JAIDS Journal of Acquired Immune Deficiency Syndromes, vol.26, issue.2, pp.159-63, 2001.
DOI : 10.1097/00126334-200102010-00008

A. Moore, C. Sabin, M. Johnson, and A. Phillips, Gender and Clinical Outcomes After Starting Highly Active Antiretroviral Treatment: A Cohort Study, JAIDS Journal of Acquired Immune Deficiency Syndromes, vol.29, issue.2, pp.197-202, 2002.
DOI : 10.1097/00042560-200202010-00015

R. Moore, I. Fortgang, J. Keruly, and R. Chaisson, Adverse Events from Drug Therapy for Human Immunodeficiency Virus Disease, The American Journal of Medicine, vol.101, issue.1, pp.34-40, 1996.
DOI : 10.1016/S0002-9343(96)00077-0

J. Mrus, P. Williams, J. Tsevat, S. Cohn, and A. Wu, Gender differences in health-related quality of life in patients with HIV/AIDS, Quality of Life Research, vol.339, issue.2, pp.479-91, 2005.
DOI : 10.1007/s11136-004-4693-z

T. Neumann, T. Woiwod, A. Neumann, B. Ross, V. Birgelen et al., Cardiovascular risk factors and probability for cardiovascular events in HIV-infected patients. Part II: gender differences, Eur J Med Res, vol.9, issue.2, pp.55-60, 2004.

E. Nicastri, C. Angeletti, L. Palmisano, L. Sarmati, A. Chiesi et al., Gender differences in clinical progression of HIV-1-infected individuals during long-term highly active antiretroviral therapy, AIDS, vol.19, issue.6, pp.577-83, 2005.
DOI : 10.1097/01.aids.0000163934.22273.06

M. Nunez and V. Soriano, Hepatotoxicity of antiretrovirals: incidence, mechanisms and management, Drug Saf, vol.28, issue.1, pp.53-66, 2005.

N. Pai, J. Lawrence, A. Reingold, and J. Tulsky, Structured treatment interruptions (STI) in chronic unsuppressed HIV infection in adults, Cochrane Database Syst Rev, vol.3, p.6148, 2006.

S. Perez-hoyos, J. Del-amo, R. Muga, J. Del-romero, P. Garcia-de-olalla et al., Effectiveness of highly active antiretroviral therapy in Spanish cohorts of HIV seroconverters, AIDS, vol.17, issue.3, pp.353-362, 2003.
DOI : 10.1097/00002030-200302140-00009

M. Prins, J. Robertson, R. Brettle, I. Aguado, B. Broers et al., Do gender differences in CD4 cell counts matter?, AIDS, vol.13, issue.17, pp.2361-2365, 1999.
DOI : 10.1097/00002030-199912030-00007

M. Ritchie, D. Haas, A. Motsinger, J. Donahue, H. Erdem et al., Drug Transporter and Metabolizing Enzyme Gene Variants and Nonnucleoside Reverse-Transcriptase Inhibitor Hepatotoxicity, Clinical Infectious Diseases, vol.43, issue.6, pp.779-82, 2006.
DOI : 10.1086/507101

URL : http://cid.oxfordjournals.org/cgi/content/short/43/6/779

K. Scarsi and M. Postelnick, The impact of gender and pregnancy on antiretroviral therapy for HIV: pharmacokinetic and disease-related differences, J Gend Specif Med, vol.6, issue.1, pp.7-16, 2003.

C. Tamalet, J. Fantini, C. Tourres, and N. Yahi, Resistance of HIV-1 to multiple antiretroviral drugs in France, AIDS, vol.17, issue.16, pp.2383-2391, 2003.
DOI : 10.1097/00002030-200311070-00014

I. Tiembre, S. Dagnan, J. Benie, D. Ekra, N. Dm et al., Seroprevalence du VIH au dispensaire antivenerien de l' Institut national d' hygiene publique d' Abidjan Prevalence of HIV infection on patients of anti venereal center of the National Institute of Public Hygiene Abidjan, Bulletin de la Societe de pathologie exotique, vol.97, issue.5, pp.334-335, 2004.

T. Villameytide, M. Fernandez-guerrero, and M. , Litiasis renal inducida por indinavir, Actas Urol??gicas Espa??olas, vol.28, issue.7, pp.523-529, 2004.
DOI : 10.1016/S0210-4806(04)73122-8

A. Tramarin, M. Jp, S. Gerzeli, S. Campostrini, and F. Starace, The clinical and economic efficacy of HAART: a shift from inpatient medical to outpatient pharmaceutical care for HIV/AIDS patients in Northeastern Italy, AIDS Care, vol.13, issue.2, pp.213-221, 2004.
DOI : 10.1097/00042560-199804010-00010

N. Viget and Y. Yazdanpanah, Quand et comment commmencer un traitement antirétroviral, La revue du Praticien, vol.56, issue.9, pp.953-962, 2006.